×
About 400 results

ALLMedicine™ Waldenstrom Macroglobulinemia Center

Research & Reviews  119 results

Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rar...
https://doi.org/10.1016/j.clml.2022.04.008
Clinical Lymphoma, Myeloma & Leukemia; Kline KAF, Lee ST et. al.

May 8th, 2022 - Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rare transformation or unhappy coincidence?|2022|Kline KAF,Lee ST,Law JY,Kallen M,|

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02952508

May 6th, 2022 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT01198067

Apr 27th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity profile of pomalidomide in pat...

Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
https://doi.org/10.1080/14737140.2022.2064849
Expert Review of Anticancer Therapy; Sarosiek S, Sermer D et. al.

Apr 12th, 2022 - The development of Bruton tyrosine kinase (BTK) inhibitors has significantly changed the treatment landscape for patients with Waldenström macroglobulinemia (WM). Ibrutinib was the first BTK inhibitor to receive FDA approval for this disease, but ...

Research progress on epigenetics of small B-cell lymphoma.
https://doi.org/10.1007/s12094-022-02820-z
Clinical & Translational Oncology : Official Publication ... Ruan X, Zhang R et. al.

Mar 26th, 2022 - Small B-cell lymphoma is the classification of B-cell chronic lymphoproliferative disorders that include chronic lymphocytic leukaemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic...

see more →

Clinicaltrials.gov  11 results

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02952508

May 6th, 2022 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT01198067

Apr 27th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity profile of pomalidomide in pat...

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
https://clinicaltrials.gov/ct2/show/NCT01177527

Mar 17th, 2022 - Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking proced...

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicul...
https://clinicaltrials.gov/ct2/show/NCT01381692

Oct 4th, 2021 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of temsirolimus in combination with bortezomib, rituximab, dexamethasone in patients with relapsed Waldenstrom's macroglobulinemia and relapsed/refractory mantle cell, follicular...

Ibrutinib and Ixazomib Citrate in Treating Patients With Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT03506373

Aug 9th, 2021 - PRIMARY OBJECTIVE: I. To determine the efficacy (as assessed by complete response [CR] rate) of the combination of ixazomib citrate (ixazomib) and ibrutinib in Waldenstrom macroglobulinemia (WM) patients. SECONDARY OBJECTIVES: I. To assess the ove...

see more →

News  26 results

When to Treat as Important as Which Drug to Use in WM
https://www.medscape.com/viewarticle/961877

Oct 29th, 2021 - When to initiate treatment is as important as what to use for the treatment of patients newly diagnosed with Waldenstrom macroglobulinemia (WM), a leading expert in the disease emphasizes. "We have to be very careful not to tell patients they have...

Looking Ahead in Treating Follicular Lymphoma
https://www.onclive.com/view/looking-ahead-in-treating-follicular-lymphoma

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Let’s talk about BTK [Bruton tyrosine kinase] inhibitors in follicular lymphoma. I think they’re commonly prescribed, more commonly than you would imagine in the relapsed setting in patients with that. That’s...

FDA Approval in Waldenstrom Macroglobulinemia, Priority Review and sNDA in Multiple Myeloma, and More
https://www.onclive.com/view/fda-approval-in-waldenstrom-macroglobulinemia-priority-review-and-snda-in-multiple-myeloma-and-more

Apr 2nd, 2021 - Today- An FDA approval in Waldenstrom macroglobulinemia, a priority review in multiple myeloma, a new drug application submitted in myeloma, European approvals of chimeric antigen receptor T-cell therapies, and a US Preventative Task Force scre...

Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia
https://www.medscape.com/viewarticle/944782

Jan 27th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...

Ofatumumab to Be Available Through a Patient Access Program for CLL
https://www.onclive.com/view/ofatumumab-to-be-available-through-a-patient-access-program-for-cll

Dec 20th, 2020 - Patients with chronic lymphocytic leukemia (CLL) who are being treated with ofatumumab (Arzerra) will soon have to get their therapy through an oncology patient access program, as Novartis, the manufacturer, will no longer be selling the drug comm...

see more →

Patient Education  4 results see all →